Literature DB >> 28087349

Combination of Multiple Ligation-Dependent Probe Amplification and Illumina MiSeq Amplicon Sequencing for TSC1/TSC2 Gene Analyses in Patients with Tuberous Sclerosis Complex.

Nur Farrah Dila Ismail1, Abdul Qawee Rani2, Nik Mohd Ariff Nik Abdul Malik1, Chia Boon Hock3, Siti Nabilahuda Mohd Azlan4, Salmi Abdul Razak5, Wee Teik Keng6, Lock Hock Ngu6, Abdul Rashid Silawati7, Nor Azni Yahya8, Narazah Mohd Yusoff9, Teguh Haryo Sasongko10, Z A M H Zabidi-Hussin11.   

Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous disorder characterized by tumor growth in multiple organs and caused by mutations in either TSC1 or TSC2 genes. Because of their relatively large genomic sizes, absence of hotspots, and common type of mutations, mutation detection in TSC1 and TSC2 genes has been challenging. We devised a combination of multiple ligation-dependent probe amplification (MLPA) and amplicon sequencing (AS) to simplify the detection strategy, yet we come up with reasonably high detection rate. Thirty-four Malaysian patients diagnosed with TSC were referred to Human Genome Center, Universiti Sains Malaysia. We used a combination of MLPA to detect large copy number changes and AS to detect smaller mutations. TSC1 pathogenic or likely pathogenic mutations were found in 6 patients (18%) and TSC2 in 21 patients (62%), whereas 6 patients (18%) show no mutations and 1 patient (2%) showed only TSC2 missense variant with uncertain significance. Six of the mutations are novel. Our detection strategy costs 81% less and require 1 working week less than the conventional strategy. Confirmatory sequencing using Sanger method on a few representative mutations showed agreement with results of the AS. Combination of MLPA and Illumina MiSeq AS provides a simplified strategy and reasonably high detection rate for TSC1/TSC2 mutation, which suggested application of the strategies into clinical molecular diagnostics.
Copyright © 2017 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28087349     DOI: 10.1016/j.jmoldx.2016.10.009

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  5 in total

1.  Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations: Molecular Analysis Supports an Expanding Clinicopathologic Spectrum.

Authors:  Doreen N Palsgrove; Yunjie Li; Christine A Pratilas; Ming-Tseh Lin; Aparna Pallavajjalla; Christopher Gocke; Angelo M De Marzo; Andres Matoso; George J Netto; Jonathan I Epstein; Pedram Argani
Journal:  Am J Surg Pathol       Date:  2018-09       Impact factor: 6.394

2.  Pattern of TSC1 and TSC2 germline mutations in Russian patients with tuberous sclerosis.

Authors:  Evgeny N Suspitsin; Grigoriy A Yanus; Marina Yu Dorofeeva; Tatiana A Ledashcheva; Nataliya V Nikitina; Galina V Buyanova; Elena V Saifullina; Anna P Sokolenko; Evgeny N Imyanitov
Journal:  J Hum Genet       Date:  2018-02-23       Impact factor: 3.172

3.  Early diagnosis of a newborn with tuberous sclerosis caused by a genetic mutation.

Authors:  Lin Qiao; Yuting Yang; Dongmei Yue
Journal:  J Int Med Res       Date:  2021-08       Impact factor: 1.671

4.  Low-level mosaicism in tuberous sclerosis complex in four unrelated patients: Comparison of clinical characteristics and diagnostic pathways.

Authors:  Héctor Hugo Manzanilla-Romero; Denisa Weis; Simon Schnaiter; Sabine Rudnik-Schöneborn
Journal:  Am J Med Genet A       Date:  2021-07-30       Impact factor: 2.578

5.  A novel de novo TSC2 nonsense mutation detected in a pediatric patient with tuberous sclerosis complex.

Authors:  Mei-Hua Yang; Zhong-Ke Wang; Yi Huang; Sheng-Qing Lv; Chun-Qing Zhang; Yuan-Yuan Zhu; Qing-Wu Yang; Shi-Yong Liu
Journal:  Childs Nerv Syst       Date:  2020-06-12       Impact factor: 1.532

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.